BGD Share Price | Biogened SA Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Compare Biogened SA with Similar Stocks

Bioceltix SA Molecure SA BIOTON SA

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a growth in Net Profit of 10.58%, the company declared Very Positive results in Mar 26

OPERATING CASH FLOW(Y) Highest at PLN 9.38 MM
RAW MATERIAL COST(Y) Fallen by -6.07% (YoY)
CASH AND EQV(HY) Highest at PLN 13.46 MM

With ROE of 10.30%, it has a attractive valuation with a 0.96 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

PLN 45 Million (Micro Cap)

P/E

9.00

Industry P/E

Dividend Yield

135.87%

Debt Equity

0.40

Return on Equity

10.30%

Price to Book

0.96

Revenue and Profits:

Net Sales:

28 Million

(Quarterly Results - Mar 2026)

Net Profit:

3 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

2.22%

6 Months

-14.81%

1 Year

-23.97%

2 Years

-22.03%

3 Years

15.0%

4 Years

46.03%

5 Years

50.82%

Biogened SA for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

17.18%

EBIT Growth (5y)

24.18%

EBIT to Interest (avg)

4.85

Debt to EBITDA (avg)

1.29

Net Debt to Equity (avg)

0.40

Sales to Capital Employed (avg)

1.71

Tax Ratio

33.00%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

16.92%

ROE (avg)

8.84%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.96

EV to EBIT

6.73

EV to EBITDA

4.53

EV to Capital Employed

0.97

EV to Sales

0.58

PEG Ratio

4.93

Dividend Yield

135.87%

ROCE (Latest)

14.40%

ROE (Latest)

10.30%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

Bearish

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is -13.98% vs 11.15% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 13.04% vs 9.52% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "28.30",
          "val2": "32.90",
          "chgp": "-13.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "6.00",
          "val2": "5.60",
          "chgp": "7.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.90",
          "val2": "1.00",
          "chgp": "-10.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2.60",
          "val2": "2.30",
          "chgp": "13.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "164.40%",
          "val2": "136.40%",
          "chgp": "2.80%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 1.98% vs 16.00% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -15.52% vs 13.73% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "113.10",
          "val2": "110.90",
          "chgp": "1.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "12.90",
          "val2": "13.90",
          "chgp": "-7.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.60",
          "val2": "2.50",
          "chgp": "4.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "4.90",
          "val2": "5.80",
          "chgp": "-15.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "75.70%",
          "val2": "88.10%",
          "chgp": "-1.24%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY

Mar'26

Mar'25

Change(%)

Net Sales

28.30

32.90

-13.98%

Operating Profit (PBDIT) excl Other Income

6.00

5.60

7.14%

Interest

0.90

1.00

-10.00%

Exceptional Items

0.00

Consolidate Net Profit

2.60

2.30

13.04%

Operating Profit Margin (Excl OI)

164.40%

136.40%

2.80%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2026 is -13.98% vs 11.15% in Mar 2025

Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is 13.04% vs 9.52% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

113.10

110.90

1.98%

Operating Profit (PBDIT) excl Other Income

12.90

13.90

-7.19%

Interest

2.60

2.50

4.00%

Exceptional Items

0.00

Consolidate Net Profit

4.90

5.80

-15.52%

Operating Profit Margin (Excl OI)

75.70%

88.10%

-1.24%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 1.98% vs 16.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -15.52% vs 13.73% in Dec 2024

All Annual Results

Company CV

About Biogened SA

Biogened SA

Pharmaceuticals & Biotechnology

Biogened SA is a Poland-based company active in the healthcare sector. The Company is engaged in production and distribution of generic pharmaceuticals in psychiatry, neurology and oncology, as well as development, production and distribution of dermocosmetics and diet supplements. The Company’s product portfolio includes: Polmantis and SST Salvia Stimulating Tablets (pharmaceuticals), Dermedic, Ellexir, Herba Botanic and Novoscabin (dermocosmetics), and Fibers, Prolady, Futimal and Dermedic Caps (diet supplemenst). As of March 31, 2012, Life Science Technologies NV held an 80.92% stake in the capital.

Company Coordinates

Company Details

Ul. Pojezierska 99 , LODZ None : 91-342

Tel: 48 42 6513152

http://www.biogened.pl/

Registrar Details